LATA HIV Injectable Trial Results
Analysis based on 13 articles · First reported Sep 17, 2026 · Last updated Sep 22, 2026
The results could support broader uptake of long-acting injectable HIV regimens, a positive long-term signal for the pharmaceutical companies supplying cabotegravir and rilpivirine, though near-term revenue impact is limited by cost and access barriers in low-income settings. Overall market impact is modest, as the trial is a clinical and public-health development rather than a commercial or macroeconomic event.
A UCL-led clinical trial in Africa, the LATA (Long-Acting Treatment in Adolescents) trial, found that long-acting injectable antiretroviral therapy given every eight weeks was more effective than daily tablets at maintaining viral suppression in adolescents living with HIV. The trial enrolled 476 adolescents aged 12 to 19 across five clinics in Kenya, South Africa, Uganda and Zimbabwe, randomly assigning them to daily tablets or the injectable combination of cabotegravir and rilpivirine. After 96 weeks, only 2 participants (1%) on injectables experienced confirmed viral rebound versus 15 (6%) on daily tablets, and 94% of the injectable group said the eight-weekly injections were much easier than daily medication. Results were published in The Lancet. Researchers, including chief investigator Professor Sarah Pett and Dr Mutsa Bwakura-Dangarembizi, called for wider availability of injectables in Africa, where nine out of ten adolescents with HIV live but the treatment is largely unavailable outside a few clinics. Challenges cited include higher cost due to patents, refrigeration requirements for rilpivirine, and the need for skilled nursing staff. The World Health Organization currently recommends injectables only as an alternative option for adults and adolescents on daily tablets who are successfully suppressing the virus and do not have active hepatitis B; this stance may be strengthened by the findings. The trial was funded by the European Union through EDCTP-2 and Johnson & Johnson Innovative Medicines, which provided rilpivirine, while ViiV Healthcare provided cabotegravir. UCL was the sponsor, with collaboration from institutions including the London School of Hygiene and Tropical Medicine, Radboud University Medical Center, University of York, Baylor College of Medicine, Moi University and University of Zimbabwe.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard